Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia

Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust (Other)
Overall Status
Recruiting
CT.gov ID
NCT05718960
Collaborator
(none)
50
1
2
11
4.6

Study Details

Study Description

Brief Summary

Functional dyspepsia is common, affecting 7.2% of the global population, and associated with substantial health impairment. Almost 80% of patients with functional dyspepsia report meal-related symptoms and are classified as having the postprandial distress syndrome (PDS) variant. However, studies evaluating dietary modifications in PDS are sparse.

The investigators will perform a single-centre randomised trial evaluating traditional dietary advice (TDA) in PDS.

50 patients with PDS will be randomly assigned to a leaflet explaining reassurance-alone +/- TDA. The reassurance-alone group will be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia. The TDA group will receive the same information but also be recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre.

Questionnaires are to be completed during the 4-week trial, including self-reported adequate relief of dyspeptic symptoms, and the validated Leuven Postprandial Distress Scale (LPDS), Gastrointestinal Symptom Rating Scale, and Napean Dyspepsia Quality of Life Index.

The primary endpoint(s) to define clinical response will be evaluated over weeks 3-4 as, i) ≥50% adequate relief of dyspeptic symptoms, and ii) >0.5-point reduction in the PDS subscale of the LPDS (calculated as the mean scores for early satiety, postprandial fullness, and upper abdominal bloating).

Condition or Disease Intervention/Treatment Phase
  • Other: Reassurance-alone
  • Behavioral: Traditional dietary advice
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Randomised Trial of Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia
Actual Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Jan 30, 2023
Anticipated Study Completion Date :
Aug 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Reassurance-alone

Other: Reassurance-alone
To be informed of the absence of organic disease and provided a diagnostic explanation of functional dyspepsia

Active Comparator: Traditional Dietary Advice

Behavioral: Traditional dietary advice
To receive the same information as reassurance-alone group but also recommended to eat smaller, regular meals and reduce the intake of caffeine/alcohol/fizzy drinks, fatty/processed/spicy foods, and fibre

Outcome Measures

Primary Outcome Measures

  1. Proportion of clinical responders between traditional dietary advice vs. reassurance alone based on the leuven postprandial distress scale (LPDS) [4 weeks]

    The Leuven Postprandial Distress Scale (LPDS) assesses the severity of 8 upper gastrointestinal symptoms scored from 0 (none) to 4 (very severe). A difference of 0.7 from baseline for the cardinal PDS symptoms (average of first 3 questions) will be used as a cut-off to determine clinical response by comparing averaged pre-treatment scores with the average score during the weeks 3-4.

  2. Proportion of clinical responders between traditional dietary advice vs. reassurance alone [4 weeks]

    Self-reported adequate relief of dyspeptic symptoms as a binary answer (yes or no). A responder will be defined if ≥50% adequate relief of dyspeptic symptoms during weeks 3-4

Secondary Outcome Measures

  1. Changes in Gastrointestinal Symptom Rating Irritable Bowel syndrome Scale [4 weeks]

    The validated Gastrointestinal Symptom Rating Scale assesses the symptoms of irritable bowel syndrome, depicting problems with satiety, abdominal pain, diarrhoea, constipation and bloating. Higher scores represent greater symptom severity. Change in monthly scores will be compared within- and between-treatments for both cohorts combined.

  2. Changes in Napean Dyspepsia-related Quality of Life Index [4 weeks]

    The Napean Dyspepsia Scale is a validated questionnaire assessing dyspepsia-related quality of life syndrome, with higher scores representing worse quality of life. Change in monthly scores will be compared within- and between-treatments for both cohorts combined.

  3. Changes in Hospital Anxiety and Depression scale [4 weeks]

    The Hospital Anxiety and Depression Scale is a validated questionnaire assessing mood, with higher scores representing worse mood. Change in monthly scores will be compared within- and between-treatments for both cohorts combined.

  4. Changes in Somatic Symptom reporting [4 weeks]

    The validated patient health questionnaire-12 assess extra-intestinal somatic symptoms, with higher scores representing greater somatic symptom severity. Change in monthly scores will be compared within- and between-treatments for both cohorts combined.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Fulfil Rome IV symptoms criteria for functional dyspepsia

  • Normal upper gastrointestinal endoscopy within last 3 years

  • Online access

  • English literate

Exclusion Criteria:
  • Organic gastrointestinal diseases (e.g. inflammatory bowel disease, GI cancer, coeliac disease)

  • Major abdominal surgery (except laparoscopy, appendectomy, cholecystectomy)

  • Documented H.pylori in the last 3 months

  • History of eating disorders

  • Body mass index <20

  • Current use of opioids or anti-inflammatory drugs

  • Severe systemic disease (e.g. cardiac, renal, respiratory) necessitating frequent medical consultations

  • Pregnant

  • Diabetes mellitus

  • Scleroderma

  • Memory impairment

  • Current dietary interventions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal Hallamshire Hospital Sheffield South Yorkshire United Kingdom S10 2JF

Sponsors and Collaborators

  • Sheffield Teaching Hospitals NHS Foundation Trust

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Imran Aziz, Principal Investigator, Sheffield Teaching Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT05718960
Other Study ID Numbers:
  • 259079
First Posted:
Feb 8, 2023
Last Update Posted:
Feb 10, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 10, 2023